Breaking News
Get 55% Off 0
🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAY
CLAIM SALE
Close

Halozyme Therapeutics Inc (HALO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Halozyme's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
60.98 +1.33    +2.23%
07:59:59 - Closed. Currency in USD
After Hours
60.00
-0.99
-1.62%
11:00:39 - Real-time Data
  • Volume: 1,115,711
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 59.14 - 61.19
Type:  Equity
Market:  United States
Halozyme 60.98 +1.33 +2.23%

HALO Financial Summary

 
A brief financial summary of Halozyme Therapeutics Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Halozyme Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported revenue was USD 290.08 million compared to USD 216.03 million a year ago. Net income was USD 137.01 million compared to USD 81.84 million a year ago. Basic earnings per share from continuing operations was USD 1.08 compared to USD 0.62 a year ago. Diluted earnings per share from continuing operations was USD 1.05 compared to USD 0.61 a year ago. For the nine months, revenue was USD 717.32 million compared to USD 599.21 million a year ago. Net income was USD 307.08 million compared to USD 196.21 million a year ago. Basic earnings per share from continuing operations was USD 2.42 compared to USD 1.48 a year ago. Diluted earnings per share from continuing operations was USD 2.37 compared to USD 1.45 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

HALO Income Statement

Gross margin TTM 73.65%
Operating margin TTM 50.62%
Net Profit margin TTM 41.43%
Return on Investment TTM 22.79%
 Total Revenue  Net Income
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Revenue 290.08 231.35 195.88 230.04
Gross Profit 222.2 170.71 148.44 156.4
Operating Income 163.2 117.24 95.54 103.54
Net Income 137.01 93.24 76.82 85.39

HALO Balance Sheet

Quick Ratio MRQ 8.75
Current Ratio MRQ 10.36
LT Debt to Equity MRQ 332.26%
Total Debt to Equity MRQ 332.26%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Assets 2118.03 1969.45 1841.53 1733.27
Total Liabilities 1665.33 1680.03 1663.72 1649.46
Total Equity 452.7 289.42 177.81 83.81

HALO Cash Flow Statement

Cash Flow/Share TTM 3.18
Revenue/Share TTM 7.48
Operating Cash Flow  106.03%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 115.38 55.79 129.43 102.35
Cash From Investing Activities -167.48 -42.04 -82.68 -8.29
Cash From Financing Activities 18.56 9.48 -0.489 -249.92
Net Change in Cash -33.55 23.24 46.26 -155.86
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HALO Comments

Write your thoughts about Halozyme Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email